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Background. CXCL12a, a chemokine that importantly promotes the oriented cell migration and tissue homing of many cell
types, regulates key homeostatic functions and pathological processes through interactions with its cognate receptor (CXCR4)
and heparan sulfate (HS). The alternative splicing of the cxcl12 gene generates a recently identified isoform, CXCL12c, which
structure/function relationships remain unexplored. The high occurrence of basic residues that characterize this isoform
suggests however that it could feature specific regulation by HS. Methodology/Principal Findings. Using surface plasmon
resonance and NMR spectroscopy, as well as chemically and recombinantly produced chemokines, we show here that CXCL12c
first 68 amino acids adopt a structure closely related to the well described a isoform, followed by an unfolded C-terminal
extension of 30 amino acids. Remarkably, 60 % of these residues are either lysine or arginine, and most of them are clustered in
typical HS binding sites. This provides the chemokine with the highest affinity for HP ever observed (Kd=0.9 nM), and ensures
a strong retention of the chemokine at the cell surface. This was due to the unique combination of two cooperative binding
sites, one strictly required, found in the structured domain of the protein, the other one being the C-terminus which essentially
functions by enhancing the half life of the complexes. Importantly, this peculiar C-terminus also regulates the balance between
HS and CXCR4 binding, and consequently the biological activity of the chemokine. Conclusions/Significance. Together these
data describe an unusual binding process that gives rise to an unprecedented high affinity between a chemokine and HS. This
shows that the c isoform of CXCL12, which features unique structural and functional properties, is optimized to ensure its
strong retention at the cell surface. Thus, depending on the chemokine isoform to which it binds, HS could differentially
orchestrate the CXCL12 mediated directional cell kinesis.
Citation: Laguri C, Sadir R, Rueda P, Baleux F, Gans P, et al (2007) The Novel CXCL12c Isoform Encodes an Unstructured Cationic Domain Which
Regulates Bioactivity and Interaction with Both Glycosaminoglycans and CXCR4. PLoS ONE 2(10): e1110. doi:10.1371/journal.pone.0001110
INTRODUCTION
CXCL12, also known as SDF-1 (Stromal cell-Derived Factor-1),
belongs to the growing family of chemokines, a group comprising
some fifty low molecular weight proteins, best known to mediate
leukocyte trafficking and activation [1]. CXCL12, initially
identified from bone marrow stromal cells and characterized as
a pre-B-cell stimulatory factor [2], is constitutively expressed
within tissues during organogenesis and adult life [3,4]. This
chemokine, highly conserved among mammalian species, is a key
regulator of oriented cell migration. As such, it orchestrates a very
large array of functions, both during development and adult life
[5–9] and is also importantly involved in a number of pathogenic
mechanisms [10,11]. These physiopathological effects are medi-
ated by the G-protein coupled receptor CXCR4, to which the
chemokine binds and triggers cell signaling [6,12]. In addition to
these physiological functions, CXCL12 is a potent inhibitor of the
cellular entry of CXCR4-dependent human immunodeficiency
virus [12]. Recently, we have documented that CXCR7 (RDC-1),
also binds to- and is activated by- CXCL12 [13], although the
biological role played by this couple remains to be further
characterized.
From a structural view point, CXCL12 has a typical chemokine
fold stabilized by two disulfide bonds: it consists of a poorly
structured N-terminus of 10 residues, followed by a long loop, a 310
helix, a three stranded b-sheet and a C-terminal a-helix. Up to
recently, two CXCL12 isoforms, arising from the alternative
splicing of a single gene [14] have been studied. The predominant
a form encodes a 68 amino acid peptide, while the b one contains
four additional amino acids at the C terminus. Most functional
data on CXCL12 were obtained from CXCL12a and b, while to
date, three isoforms (a, b and c) and up to six isoforms (a, b, c, d, e
and w) of CXCL12 have been found in rodents [15] and human
[16], respectively. All these isoforms share the same three first
exons corresponding to the a isoform (residues 1 to 68), but differ
in their fourth exon, which gives rise to a specific C-terminal
domain for each of them.
It has become clear that biological information required to run
the chemokine system is not only stored in the sequences of the
proteins involved, but also in the structure of a class of
polysaccharide called glycosaminoglycans (GAGs), in particular
heparan sulfate (HS), to which most chemokines bind [17]
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proteins to form proteoglycans, these complex polysaccharides are
ubiquitously found on the cell surface and within the extracellular
matrix [18]. These molecules have a unique molecular design in
which sulfated disaccharide units are clustered in specific domains
of variable length and sulfation profile, providing the chain a large
array of different protein binding sites [19]. HS are importantly
implicated in the regulation of the proteins they bind, and have
recently emerged as critical regulators of many events involving
cell response to external stimuli. Current models suggested that
HS enhance chemokine immobilization and forms haptotactic
gradients of the protein along cell surfaces, hence providing
directional cues for migrating cells [20], protects chemokines from
enzymatic degradation [21], and promotes local high concentra-
tions at the cell surface, facilitating receptor binding and
downstream signaling (for review see [22]). In vivo data support
the view that, within tissues, CXCL12 is sequestered by HS [23].
CXCL12a binding to HS critically involves amino acids K24
and K27, which together with R41 form the essential part of the
HS-binding site [24] and are distinct from those required for
binding to CXCR4. Given that the minor d, e and w isoforms lack
any recognizable HS-binding motif in their carboxy-termini, it can
be hypothesized that like CXCL12a, the K24-K27-R41 epitope
recapitulates their ability to interact with HS. The situation could
be radically different for the novel CXCL12c isoform. It is indeed
characterized by a distinctive 30 amino acids long C-terminal
peptide, remarkably conserved between rodents and human,
which contains as much as 18 basic residues (B), 9 of which being
clustered into three putative BBXB HS-binding domains (Fig. 1A).
The existence of carboxy-encoded HS-binding motifs suggests that
this isoform could interact with enhanced affinity and/or different
selectiveness with GAGs to accomplish specific functions.
However, the structure/function relationships of this very peculiar
CXCL12 isoform have not been explored yet. Here, we show that
CXCL12c 1 to 68 domain adopts a structure closely related to the
a isoform and has an unstructured C-terminal region. This
domain reduces CXCR4 occupancy, but in contrast broadens the
spectrum of GAG to which the chemokine binds. Moreover, it
stabilizes the CXCL12c/HS complex and, in cooperation with the
K24-R41 epitope, provides the chemokine with the highest affinity
for GAGs ever observed for any chemokine.
RESULTS AND DISCUSSION
Wild type and mutants CXCL12 production
The CXCL12c cDNA, obtained from Balb/C mouse brain mRNA
was cloned and over expressed in E. coli, purified to homogeneity,
and characterized by mass spectrometry, NMR and amino acid
analysis. The preparation routinely yielded 4–5 mg of purified
protein per liter of bacterial culture. Wild type and mutants
CXCL12a, b and c, (Fig. 1A) were also produced by chemical
synthesis and characterized by ion spray mass spectrometry and
HPLC analysis. Final purity of all samples was found to be, on
average, in the range of 90–95%. The biological activity
(chemotaxis) of the recombinant chemokine and its chemically
synthesized homologue was identical (data not shown).
CXCL12c has a typical chemokine fold in the 1–68
domain and an unstructured C-terminal extension
CXCL12a structure has been solved both by X ray crystallogra-
phy [25,26] and NMR spectroscopy [27]. The a and b isoform
structures are similar [28] but no information has yet been
reported for CXCL12c. To perform structural and binding
studies, recombinant CXCL12c was purified from cells grown in
15NH4Cl and
13C-glucose supplemented medium. Backbone
resonances were assigned and the secondary structure content
evaluated from
13C,
15N and
1H frequencies (TALOS [29]). The
fold similarity of CXCL12c and a was assessed by recording
orientational informations (N-H
N Residual Dipolar Couplings
(RDC)) of partially aligned molecules in dilute liquid crystal [30],
and NMR relaxation experiments were used to evaluate regions of
flexibility.
The first 68 residues of CXCL12c have a spectrum very similar
to that of CXCL12a [28,31], enabling the identification of most
residues by visual inspection. This was confirmed by the complete
assignment of CXCL12c residues, but K1, E73 and K84 (Fig. 1B).
However, the assignment of CXCL12c 69–98 remains tentative
for the repeated KK motifs which present very similar backbone
chemical shifts. Secondary structure prediction from the backbone
chemical shifts indicated almost identical secondary structure
content for CXCL12a and c. Forty two N-H
N RDCs, in the 10–64
domain of CXCL12c were analyzed against CXCL12a,3 3o f
them showed an overall good correlation (Fig. 1C), which suggests
that CXCL12c 1–68 domain and CXCL12a adopt identical
tertiary structure. CXCL12c 1–68 relaxation parameters (R1, R2
and
15N-
1H NOes) were highly similar to those observed for
monomeric CXCL12a [31] with the residues 10–64 being well
structured. Residues 69–98 behaved differently: they were
clustered between 8 and 8.5 ppm in the
1H dimension, suggesting
they were poorly ordered in solution (Fig. 1D). According to
TALOS, only a few residues are predicted to adopt an extended
conformation (Fig. 1A). Seven N-H
N RDCs were observed in the c
extension between 2 and 7 Hz, presumably indicative of averaged
RDCs due to important flexibility. This domain, with negative
15N-
1H NOes and low R1 and R2 relaxation rates compared to
the protein core, experienced fast timescale dynamics, confirming
it was highly disordered in solution. Together, these data show that
the C-terminal peptide is disordered and has no major effect on
the structure of the first 68 residues of CXCL12c.
The prevalence of such non structured protein segments,
recently became increasingly recognized [32]. These domains,
known as intrinsically disordered or natively unfolded, usually
feature a unique combination of low overall hydrophobicity and
high net charge, a point that clearly characterize the CXCL12c C-
terminal peptide. Proteins with such disordered regions are
believed to performed critical functions, including molecular
recognition through large and accessible interaction surfaces. In
view of the highly basic nature of the CXCL12c C-terminal
domain, its disordered state, and the importance of GAG
recognition for chemokine function, we then investigated the
ability of CXCL12c to interact with a variety of GAGs, including
heparin (HP) HS, and dermatan sulfate (DS), and compared it to
that of CXCL12a, b, which C-termini are distinct.
CXCL12a, b and c differently bind to GAGs
To determine the GAG binding ability of CXCL12a, b and c
isoforms we adopted a solid phase assay, in which reducing end
biotinylated HP, HS or DS were captured on top of a streptavidin
coated sensorchip, a system that mimics, to some extent, the cell
membrane-anchored proteoglycans. Surface plasmon resonance
(SPR) real time monitoring was exploited to measure changes in
refractive index caused by the binding of chemokines to each of
the immobilized GAGs.
Binding curves, obtained when the CXCL12 isoforms were
flowed over the HP, HS and DS surfaces, showed marked
differences (Fig. 2). These experiments first indicated that while
CXCL12c interacts with HP, HS and DS, CXCL12a and b only
recognize HP and HS, suggesting that the C-terminal domain,
CXCL12c and Glycosaminoglycans
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the range of GAGs to which it binds. Visual inspection of the
sensorgrams also showed major differences during the dissociation
phase. CXCL12a dissociated from the immobilized GAGs rapidly
(binding curves returned to the base line within a minute), while
CXCL12c formed tight complexes, and CXCL12b displayed an
intermediate behaviour. Preliminary analysis of the binding curves
indicated that the binding rates were dominated by mass transfer,
and global fitting of the binding curve returned values with low
significances (see below). Because we generated data in which the
association phase was allowed to proceed to equilibrium, affinity
data were derived independently from the kinetic. By plotting
Req/C against Req for different concentrations of chemokine (in
which Req are the steady state values at equilibrium and C the
concentrations of injected chemokine), straight lines were obtained
(data not shown) which slopes, corresponding to the equilibrium
constant Kd, are reported in Table 1. These analyses demon-
strated that CXCL12c interacts with GAGs with an unprecedent-
ed propensity, featuring a 2 log increase compared to CXCL12a,
and suggesting a strong participation of the C-terminal domain in
the binding reaction.
Heparin derived oligosaccharides interact with
CXCL12c C-terminal domain and reduce its mobility
In view of the above data, which support the existence of
additional GAG binding sites within the C-terminal domain of
CXCL12c, we performed titration experiments of
15N-CXCL12c
with different HP derived di-(dp2), tetra-(dp4) and octa-(dp8)
saccharides. The CXCL12c/oligosaccharide interactions were in
fast exchange regime compared to NMR chemical shift timescale,
typical of interactions in the mM-mM Kd range. Interaction with
Figure 1. CXCL12c has an unstructured C-terminal domain but is identical to CXCL12a in the 1-68 region. (A) Sequences of the wild type and
mutant CXCL12a, b and c isoforms produced and used in this study (mutated residues are underlined). The secondary structures of CXCL12c 1–68
domain and CXCL12a are almost identical (black boxes: a helices, white arrows: b strands, E: extended conformation). (B)
15N-HSQC spectrum of
CXCL12c (1 mM, 30uC), on which only non overlapping amide protons were indicated for clarity. Residues from the c extension are clustered between
8–8.5 ppm
1H frequency. (C) CXCL12c 1–68 domain and CXCL12a fold similarly. A good correlation (Chi
2=74) is observed between N-H
N RDCs
(CXCL12c 10–64) with RDCs backcalculated from the CXCL12a structure. (D)
15N-
1H heteronuclear NOes, longitudinal (R1; square) and transversal (R2;
triangle) relaxation rates on CXCL12c. CXCL12c is folded between residues 10 and 64 and the c extension is disordered with low NOe, R2 and R1
values.
doi:10.1371/journal.pone.0001110.g001
CXCL12c and Glycosaminoglycans
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Several resonances in the c extension were highly perturbed upon
interaction (Fig. 3A). However, they could not be individually
followed during titrations and backbone resonance assignment was
performed on the
15N-
13C-CXCL12c/dp4 complex.
Interactions of dp2, dp4 and dp8 with CXCL12c revealed two
binding domains on the protein (Fig. 3). On the CXCL12c core
region, the most perturbed residues form a continuous surface,
from R20 to R41 (Fig. 3D), including V23, K24, A40, and N45.
This binding surface suggested an oligosaccharide orientation
more or less perpendicular to the b sheet which differs from the
previously described orientation of a dp12 in complex with
a CXCL12a dimmer. In that case, the oligosaccharide also binds
K24 and R41 but is aligned along the first b strand [24]. On the
C-terminal extension, most of the residues were perturbed by the
interaction in particular residues 83 to 97. Mab 6E9, which
epitope consists of residues 78–80, still bound to the CXCL12c/
GAG complex (data not shown), further supporting the impor-
tance of the distal part of the C-terminus. Backbone chemical shifts
from CXCL12c/dp4 complex did not reveal any secondary
structural changes compared to the free protein and no
appearance of secondary structure elements in the C-terminal
extension.
15N-
1H heteronuclear NOes on the complex (data not
shown) indicated however a significant decrease in mobility upon
dp4 binding for the c extension with positive NOe values for
residues 82 to 89. A maximum NOe value around 0.2 for Q87
(data not shown) suggested nevertheless that, even in complex with
HP derived oligosaccharides, the c extension still exhibits
important flexibility.
The C-terminal domain and the binding sites in the
core structure of CXCL12c differently contribute to
the binding
To further analyze the respective GAG binding contributions of the
core region and the C-terminal domain of CXCL12, mutations
were introduced in both parts of the chemokine (see Fig. 1A) and
their binding profiles were analyzed using the SPR assay (Fig. 4). As
mentioned above, simultaneous fitting of the association and
dissociation phases was not possible, presumably due to fast on
rate which causes strong mass transport limitation during the
association phase (data not shown), and possibly rapid rebinding of
the dissociated molecules during the dissociation phase. The
dissociation rates (koff) were thus measured at the beginning of the
dissociation phase (where rebinding is limited because the number
Figure 2. Analysis of CXCL12 binding to HP, HS and DS. SPR sensorgrams measured when CXCL12 were injected over HP, HS or DS activated
sensorchips. The response in RU was recorded as a function of time for CXCL12a (26 to 300 nM), b (13 to 150 nM) and c (2.6 to 30 nM).
doi:10.1371/journal.pone.0001110.g002
Table 1. Equilibrium dissociation constant of CXCL12 for HP,
HS and DS
......................................................................
HP HS DS
CXCL12 a 9366.1 200 nM614 No binding
CXCL12 b 24.7 nM62.6 53 nM62.7 No binding
CXCL12 c 0.91 nM60.07 1.5 nM60.2 4.8 nM60.04
The equilibrium levels of bound CXCL12 were extracted from the sensorgrams
of Fig. 2 at the end of the association phases (apart from the lowest CXCL12
concentrations, which in some cases did not reach equilibrium) and used to
calculate the dissociation constant (Kd), using the Scatchard plot. Results are
expressed in nM as means6SEM of 3 to 7 experiments
doi:10.1371/journal.pone.0001110.t001
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then calculated using the equilibrium dissociation constant (kon=k-
off/Kd). Results are indicatedin Fig. 5 and show that the C-terminal
domain, while having limited effect on the on rate, essentially
determines the velocity at which the formed complex dissociates.
This is particularly marked for the c isoform, which dissociates from
HP with a koff of 0.0019 M
21s
21 compared to 0.111 M
21s
21 for
CXCL12a and 0.0204 M
21s
21 for CXCL12b. In agreement with
these observations, mutations of the 3 basic residues present at the
C-terminus of the b isoform (b-m1) did not change the on rate, but
increased the off rate to a value of 0.098 M
21s
21, thus resulting in
a behavior very close to that of CXCL12a (Fig. 5), with an overall
affinity of 125 nM for HP and 192 for HS (compare with results in
Table 1). Mutations in the core region (K24S/K27S), that
completely abolished CXCL12a binding to HP/HS [24], were
also introduced in b-m1 to yield a new mutant (b-m2; see Fig. 1). As
expected, b-m2 did not bind anymore to GAGs.
Similarly, the effect on GAG binding of mutations introduced in
the C-terminal domain of CXCL12c was analyzed. Amongst the
18 basic residues of this domain, 9 were changed for Ser which
removed the 3 typical HP binding clusters (Fig. 1A). Preliminary
analysis performed with C-terminal synthetic peptides (residues
69–98) indicated that the wild type sequence required 0.88 M
NaCl to be eluted from a HP affinity column, while the mutant
peptide eluted at 0.28 M NaCl. This mutant peptide did not show
any binding up to 200 nM using the SRP assay, demonstrating
that these mutations very strongly decreased its binding capacity
(data not shown). The GAG binding profile of the mutated full
length chemokine (c-m1, which includes these 9 mutations), was
characterized. We observed that this mutant did not bind anymore
to DS. This supports the view that the net charge of the CXCL12c
isoform C-terminal domain was involved in the broad GAG
binding activity. As could have been anticipated, c-m1 displayed
an increased dissociation rate compared to the wild type
chemokine (Fig. 5A), confirming the role of the C-terminal
domain in the complex stability. The equilibrium dissociation
constant for HP of this mutant was 10.4 nM (32 for HS). Thus,
although this C-terminal domain by itself has a highly reduced
binding capacity, the full length molecule still interacts quite
strongly with HP and HS, suggesting a predominant role for the
core domain. Consistently with this hypothesis, additional
mutations in the core structure (c-m2) dramatically decreased
HP and HS binding, supporting further the critical importance of
the core domain binding site for the interaction. CXCL12a/HP
complex displayed an half live (ln[0.5]/koff) of 6 seconds, while
CXCL12c/HP complex was characterized by a half life of
350 seconds (Fig. 5B). Together, these data show that few key
amino acids of the structured domain of CXCL12c (in particular
K24/27) constitute a strictly required binding site while, a number
of positively charged residues of the unfolded C-terminus appears
to primarily functions in stabilizing the formed complex.
Such different contributions between the two domains could be
explained by the fact that electrostatic interactions are not always
energetically positive. Favorable coulombic interactions formed in
a final complex can be some times largely offset by the desolvation
cost associated with the binding process [33], an effect that could
occur within the unfolded and largely solvent accessible C-
terminus of CXCL12c. DNA-binding domains frequently have N-
or C-terminal extensions, enriched in basic residues, and
disordered in solution. The contribution of such basic tails, which
increase the affinity for target DNA, has been studied in the
context of protein-DNA interaction [34], but to our knowledge
this has not yet been described for protein-GAG complex. In any
case, the present findings support the view that for CXCL12c,
a large and unstructured C-terminal domain functions as an
accessory ‘‘binding cassette’’ which, in cooperation with a restricted
and well defined binding site in the core structure provides very
tight binding to GAGs.
CXCL12c displays enhanced binding to cell surface
expressed HS compared to CXCL12a
To investigate whether HS, in the context of the cell surface, also
interacted more efficiently with CXCL12c than with CXCL12a,
we then compared the adsorption of these two isoforms on
CXCR4 negative CHO cells by flow cytometry. The monoclonal
antibody K15C, which recognize an epitope outside the HS
binding site and present in all CXCL12 isoforms [35] were used
for this purpose. Data are reported in Fig. 6, and show that
binding to wild type CHO-K1 cells was greatly enhanced for
CXCL12c compared to CXCL12a. In particular, at low
concentration (50 nM), CXCL12a did not displayed significant
binding, while the c isoform bound strongly to the cell surface, in
agreement with the Biacore data (Fig. 2). These interactions were
strongly reduced on HS deficient CHO-pgsD677 cells, demon-
strating the importance of HS in the binding.
CXCL12c displays reduced binging to- and signaling
through- CXCR4
To analyze the binding of CXCL12c to CXCR4, we set up an
assay, in which we compared the ability of the a and c isoforms to
compete with
125I-labeled CXCL12a. This was performed on T
lymphoblastoid cell lines (CEM or A3.01), which do not express
detectable amount of GAGs (data not shown), enabling the strict
analysis of CXCL12/CXCR4 interaction. Results showed that
CXCL12a and c, although featuring identical receptor binding
domain (localized in the N-terminus), behaved differently, the
latter showing a reduced ability to bind to CXCR4, with an IC50
of 350 nM versus 15 nM for CXCL12a. This difference clearly
relied on the C-terminal domain of CXCL12c, since specific
mutations within this domain (c-m1) restored binding to a level
comparable to that of CXCL12a (Fig. 7A). In agreement with this
r
Figure 3. The interaction of CXCL12c with dp4 and dp8 HP derived oligosaccharides reveals two main binding sites. (A) Weighted chemical shift
differences !((DdH)
2+(DdN/10)
2) of CXCL12c (0.2 mM) amide protons upon addition of dp4 (0.56 mM magenta) and dp8 (0.5 mM blue). Unassigned
amide protons are left blank. Both the core structure and the C-terminus of CXCL12c are affected upon oligosaccharide interaction. (B)
15N-HSQC in
the 1-68 domain of CXCL12c at 0 (black), 0.13 (red) 0.3 (green) and 0.5 mM (blue) dp4 concentration. (C)
15N-HSQC of CXCL12c C-terminal residues at
0 (black) and 0.5 mM (blue) dp4 concentration. Highly overlapped C-terminal assignments could not be all followed upon interaction. It is
nevertheless obvious that most residues are perturbed upon interaction with HP derived oligosaccharides. (D) Residues 69–98 of CXCL12c where
randomised by Simulating Annealing and manually attached to CXCL12a structure (PDB 1VMC). HP dp4 structure (extracted from PDB 1HPN) is also
shown. Chemical shift variations upon dp4 addition are represented on CXCL12c in yellow, orange, or red (respectively .0.03, 0.04 or 0.08 ppm) and
dark grey (not determined). A continuous binding surface is formed on CXCL12c core domain between R20 and R41 and the last 15 residues of the
protein are highly affected by the interaction.
doi:10.1371/journal.pone.0001110.g003
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intracellular calcium mobilization compared to the a isoform
(Fig. 7B).
The large amount of GAGs usually found at the cell surface, the
reduced affinity of CXCL12c for CXCR4 and its very high affinity
for HS, suggest that within tissues the c isoform might be
predominantly in a bound form, associated to GAGs, and either
stabilized to prevent proteolytic degradation and/or immobilized
to allow continued and localized stimulation of cells.
Conclusion
The binding of proteins to GAGs is the prerequisite for a large
number of cellular processes and regulatory events. The
chemokine system, in particular, strongly depends on HS, which
Figure 4. Analysis of wild type and mutant CXCL12 binding to immobilized GAGs. Binding of wild type and mutant CXCL12 were recorded as in
Fig. 2. CXCL12a (26 to 300 nM), b, b-m1, b-m2 (13 to 150 nM), c, c-m1, c-m2 (2.6 to 30 nM) were injected over GAG activated sensorchips and the
response in RU was recorded as a function of time.
doi:10.1371/journal.pone.0001110.g004
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tissues.
In this report, we have shown that CXCL12c, a new splice
variant of CXCL12, displays an unusually high affinity for GAGs
and investigated the structural determinants involved. The first 68
amino acids of the chemokine, common to all CXCL12 isoforms,
comprised both the CXCR4 binding domain and a first, well
defined, HS specific binding site. To this common platform is
added, by alternative splicing of the cxcl12 gene, different peptides
which contain a second GAG binding domain, limited to 4
additional residues for CXCL12b but as long as 30 residues for
CXCL12c. This domain, which remains unfolded, appeared to
mainly function by stabilizing the chemokine/HS complex. This,
in combination with the structured first HS binding site, provides
the protein with an unprecedented high affinity for HS. In-
terestingly, it has been described that polypeptide segments
generated by alternative splicing are mostly intrinsically disordered
[36]. This has been thought as a way to generate functional
diversity without structural modification or complication. Our
present findings fit well with this proposed mode of action. Thus,
by encoding a singular domain, bearing the CXCR4 binding site,
on which is added distinct C-terminus, CXCL12 may display
distinct regulatory functions. The observation that the different
CXCL12 isoforms mostly differ by their ability to interact with
GAGs, offers an unprecedented opportunity to ascertain the
importance of chemokine/GAG bindings in the regulation of in
vivo cell migration. Regarding CXCL12c, the remarkable
conservation within mammals, of its entire C-terminal sequence
is intriguing for a domain which presumably essentially triggers
electrostatic interactions, and argues in favor of an important role
played by this isoform. The observation that GAGs trigger a rapid
and almost irreversible accumulation of CXCL12c suggests that
within tissues it should exist essentially in a bound form in nearby
cells, presumably to allow continued and localized cellular
stimulation. These data are compatible with a selective role of
this isoform, and indicate that GAGs could be critical in
orchestrating the CXCL12 mediated migration of cells, depending
on the chemokine isoform and the nature of the GAGs to which it
binds, either during development or post-natal life.
MATERIALS AND METHODS
CXCL12 production and characterization
Murin CXCL12c cDNA was inserted in a pET17b (Novagen)
expression vector between NdeI and SpeI restriction sites, and
checked by DNA sequencing. CXCL12c was overexpressed
overnight in E. coli BL21 (DE3) cells, with 0.4 mM IPTG, either
in LB or M9 minimal medium supplemented with
15NH4Cl and
12Co r
13C- glucose for isotopic enrichment. After 30 minutes of
sonication at 4uC in 50 mM Tris pH 8.0 (buffer A), inclusion bodies
were pelleted (20000g for 15 minutes) and washed with buffer A
supplemented with 2M urea and 5 % Triton X100, then with 2 M
urea and finally with buffer A. Inclusion bodies were solubilised for
15 min at 50uC in buffer A with 7.5 M GdCl2 and 100 mM DTT.
Refolding was performed by rapid dilution with buffer A up to 1 M
GdCl2. The mixture was gently stirred overnight at 4uC after
addition of Complete protease inhibitors (Roche), then diluted 4
times with buffer A and loaded onto a 3 ml Source S column
(Amersham) equilibrated in 20 mM Na2HPO4 pH 6.0. CXCL12c
was eluted with a NaCl gradient, concentrated and further purified
on a G75 gel filtration column (Amersham) in 20 mM Na2HPO4,
150 mM NaCl pH 6.0. Purified material was analyzed by MALDI
mass spectrometry and quantified by amino acids analysis. Wild
type and mutants CXCL12a, b and c were also produced by
chemical synthesis, using the Merrifield solid-phase method and
fluorenylmethyloxycarbonyl chemistry, as described [24].
Figure 5. Association and dissociation rate constant of the CXCL12-GAG interaction. (A) Graphical summary of the data generated from the
sensorgrams of Fig. 4, in which association (kon) and dissociation (koff) rate constants of CXCL12a (open circle), b (grey circle), b-m1 (grey square), c
(black circle) and c-m1 (black square) for HP were determined as described. Differences were essentially observed along the koff axis. (B) Dissociative
half live of the different CXCL12/HP complexes.
doi:10.1371/journal.pone.0001110.g005
Figure 6. Flow cytometry analysis of CXCL12 interaction with cell
surface GAGs. CHO-K1 parental cells (squares) or HS-deficient CHO-
pgsD677 cells (triangles) were incubated with the indicated concentra-
tions of CXCL12 a (open symbols) or c (close symbols) and, after
extensive washing to remove free chemokine, were labelled with K15C
mAb and analyzed by flow cytometrey.
doi:10.1371/journal.pone.0001110.g006
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saccharides
Porcine mucosal HP was depolymerized with heparinase I. The
digestion mixture was resolved from di-(dp2) to octa-(dp18)
decasaccharide, and dp2 to dp8 were further purified by strong-
anion-exchange HPLC as described [37].
NMR experiments
NMR experiments were recorded at 30uC on Varian spectro-
meters (600 INOVA, 600 DD or 800 MHz with cryoprobe),
processed with NMRpipe and analyzed with NMRview.
CXCL12c backbone assignment and relaxation experiments were
recorded on 1 mM
15N-
13C sample in 20 mM NaH2PO4 pH 5.7,
10% D2O, 0.01% NaN3 with protease inhibitors at 600 MHz.
HNCACB, CBCA(CO)NH and HNCO,
15N-
1H NOes and T2
experiments were from Varian Biopack and T1 experiment from
[38]. Relaxation times were between 10 and 190 ms for T2 and 10
and 180 ms for T1. RDCs were measured as the difference
between isotropic (25uC) and anisotropic (34uC) IPAP experiments
[39] at 600 Mhz. 5% Bicelles (DMPC/DHPC 3:1 ratio) was used
as the alignment medium with 180 mM of CXCL12c in standard
NMR buffer. The program MODULE was used to calculate the
alignment tensor from the CXCL12a molecular shape and
evaluate the correlations between experimental and backcalcu-
lated RDCs [40]. RDC data were evaluated against all CXCL12a
published structures and fitted best 1VMC monomeric NMR
structure [41]. Residues with the lowest correlations with respect
to backcalculated data (11, 19, 20, 23, 35, 45, 46, 48 and 63) were
excluded from the fit (and the calculation of the alignment tensor).
These outliers are located mostly within regions of structural
heterogeneity between the different published structures of
CXCL12a. Titration with HP derived oligosaccharides was
performed with 200 mM
15N-CXCL12c in the NMR buffer.
Surface plasmon resonance based binding assay
Size defined HP (6 kDa), HS and DS were biotinylated at their
reducing end, and immobilized on a Biacore sensorchip. For this
purpose, flow cells of a CM4 sensorchip were functionalized with
2500 to 2800 resonance units (RU) of streptavidin as described
[24] and biotinylated HP (5 mg/ml), HS (25 mg/ml) and DS
(15 mg/ml) in HBS (10 mM HEPES, 150 mM NaCl, 3 mM
EDTA, 0.005% surfactant P20, pH 7.4) were injected across the
different flow cells to obtain immobilization levels of 40, 70 and
140 RU respectively. One flow cell was left untreated and served
as negative control. For binding assays, 250 ml of CXCL12 were
simultaneously injected, at a flow rate of 50 ml/min, over the
control and the different GAG surfaces, after which the formed
complexes were washed with running buffer for 5 min. The
sensorchip surface was regenerated with a 3 minute pulse of 2 M
NaCl. Control sensorgrams were subtracted on line from GAG
sensorgrams, and results analyzed using the Biaeval 3.1
software.
Binding of CXCL12 to CXCR4 and cell surface HS
CEM cells (10
7 cells/ml) were incubated with 0.25 nM of
125I-
CXCL12a (Perkin-Elmer, 2200 Ci/mmol) and a range of
concentrations of unlabelled CXCL12 (a, c or c-m1) in 100 ml
of PBS for 1h at 4uC. Incubations were stopped by centrifugation
at 4uC. Cell pellets were washed twice in ice-cold PBS, and the
associated radioactivity was counted. For measuring the ability of
CXCL12 to interact with cellular HS, the CXCR4 negative
CHO-K1 or HS-deficient CHO-pgsD677 (ATCC) were incubat-
ed with the ckemokine and after removal of unbound proteins,
were labelled with an anti-CXCL12 mAb (clone K15C) and a PE-
conjugated secondary antibody. Immunolabelled cells were
analysed by flow cytometry using a FacsCalibur (BD Biosciences).
Intracellular calcium release responses
Intracellular calcium measured in CXCR4-expressing cells loaded
with fluo-4-AM (Interchim) was conducted in a Mithras LB 940
counter (Berthold Technologies). Briefly, A3.01 cells were in-
cubated for 45 min at 37uC in the load buffer (10 mM Hepes,
137.5 mM NaCl, 1.25 mM CaCl2, 1.25 mM MgCl2, 0.4 mM
NaH2PO4, 1 mM KCl, 1 mM Glucose) with 0.1% of pluronic
acid and 0.5 mM of Fluo4-AM (10
6 cells/mL). After a washing
step, cells were suspended in load buffer at a final concentration of
2610
6 cells/mL and stored at 4uC. For intracellular calcium
measurements, aliquots of cells (2610
5 cells) were preincubated at
37uC for 1 min, then placed in a 96-well flat bottom plate.
Fluorescence emission was recorded at 535 nM (excitation at
485 nM) every second before (basal fluorescence) and after
programmed injection of different concentration of the ligands.
Maximum and minimum fluorescence values were determined
after addition of Triton X-100 and EDTA, respectively. Data are
expressed as fluorescence increment rate after ligand addition.
Figure 7. Comparative analysis of the CXCR4 binding and signaling properties of CXCL12a and c. (A)
125I-CXCL12a (0.25 nM) was bound to
CXCR4
+ CEM cells in the presence of cold CXCL12a (squares), c (triangle) or c-m1 (circle). (B) Intracellular calcium mobilization induced by CXCL12a
(squares), c (triangles) isoforms or CXCL12a P2G (line) in A3.01 cells. CXCL12a P2G is a non signaling mutant of CXCL12a. Data are representative of
three independent experiments.
doi:10.1371/journal.pone.0001110.g007
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